Todd Chanko

Amadeus has grown revenue and earnings despite several headwinds.

Medpace has carved out a niche helping smaller biotechs navigate the regulatory process.

GigaCloud has built a profitable niche in oversize e-commerce, pairing rapid earnings growth with an asset-light logistics model that could still leave room for the stock to climb.

Publicis is pairing AI-powered marketing with strong client retention, growing free cash flow, and a major data acquisition. Despite outperforming peers, the shares still trade at a discount.

First Advantage is growing market share in the lucrative personal verification market.

Management is delivering on its plan to expand into healthcare technology.

The stock is down 25% since our pick but we aren’t willing to wave the white flag quite yet.

Expansion into high-tech audio, fire protection, and even medical devices has the company poised for growth that isn’t reflected in its stock price.

The stock can supply portfolios with their own long-term care.

The stock has room to rebound even further, and is a buy at these levels.

The company’s history of innovation, earnings trajectory, and growth drivers makes its stock a buy.

Earnings momentum, pricing power, and barriers to entry can help the alloy manufacturer’s stock advance 42% from here.

The stock can double from here as cost savings from AI and other strategic initiatives pay off.

The stock is up 66% since Barron’s Investor Circle picked it.

The stock can rally by 75% or more in the coming 12 months.

The stock is still packed with positive catalysts.

Sonoco Products trades at a compelling valuation, especially given its growth drivers and a safe dividend yield.

The war has already taken a toll on energy infrastructure. Cactus should be a big part of the rebuilding.

Harmony Biosciences is cheap, and could double in price from current levels.

Corpay’s stock is undervalued and not priced for enough growth.